Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma

World Journal of Gastroenterology

Volumn 11, Issue 24, 2005, Pages 3719-3723

  Xu, Li Ning ^a   Zou, Sheng Quan ^a   Wang, Jian Ming ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Fas; Fas ligand; Gallbladder carcinoma; Immune escape

Indexed keywords

BIOTIN; FAS ANTIGEN; FAS LIGAND; PEROXIDASE; STREPTAVIDIN;

ADENOMA; APOPTOSIS; ARTICLE; CHRONIC CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DYSPLASIA; GALLBLADDER CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; PROTEIN EXPRESSION;

EID: 23844455250     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i24.3719     Document Type: Article

References (33)

1. Bani-Hani KE, Yaghan RJ, Matalka II, Shatnawi NJ. Gallbladder cancer in northern Jordan. J Gastroenterol Hepatol 2003; 18: 954-959
2. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003; 4: 167-176
3. Kapoor VK, McMichael AJ. Gallbladder cancer: an 'Indian' disease. Natl Med J India 2003; 16: 209-213
4. Weinstein D, Herbert M, Bendet N, Sandbank J, Halevy A. Incidental finding of gallbladder carcinoma. Isr Med Assoc J 2002; 4: 334-336
5. Pandey M, Sharma LB, Shukla VK. Cytochrome P-450 expression and lipid peroxidation in gallbladder cancer. J Surg Oncol 2003; 82: 180-183
6. Sasaki R, Takeda Y, Hoshikawa K, Takahashi M, Funato O, Nitta H, Murakami M, Kawamura H, Suto T, Yaegashi Y, Kanno S, Saito K. Long-term results of central inferior (S4a+S5) hepatic subsegmentectomy and pancreatoduodenectomy combined with extended lymphadenectomy for gallbladder carcinoma with subserous or mild liver invasion (pT2-3) and nodal involvement: a preliminary report. Hepatogastroenterology 2004; 51: 215-218
7. Shi JS, Wang JS, Liu G, Yu YL, Lu Y, Jiao XY, Yang YJ, Li GC, Han Y. Early diagnosis of primary gallbladder carcinoma. Hepatobiliary Pancreat Dis Int 2002; 1: 273-275
8. Ikeguchi M, Oi K, Hirooka Y, Kaibara N. CD8+ lymphocyte infiltration and apoptosis in hepatocellular carcinoma. Eur J Surg Oncol 2004; 30: 53-57
9. Dangles V, Validire P, Wertheimer M, Richon S, Bovin C, Zeliszewski D, Vallancien G, Bellet D. Impact of human bladder cancer cell architecture on autologous T-lymphocyte activation. Int J Cancer 2002; 98: 51-56
10. Chen GG, Lee JF, Chan UP, Xu H, Ip PC, Lau WY. Increased apoptosis in infiltrating mononuclear cells of colorectal cancer: a mechanism for tumor escape. Arch Pathol Lab Med 2002; 126: 686-691
11. Zheng J, Sun X, Chen J, Jiang F, Li W, Xie S. Mechanism of immune escape in renal cell carcinoma. Zhonghua Zhongliu Zazhi 2002; 24: 24-26
12. Phan GQ, Wang E, Marincola FM. T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. Expert Opin Biol Ther 2001; 1: 511-523
13. Chouaib S, Thiery J, Gati A, Guerra N, El Behi M, Dorothee G, Mami-Chouaib F, Bellet D, Caignard A. Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death. Tissue Antigens 2002; 60: 273-281
14. Abrahams VM, Kamsteeg M, Mor G. The Fas/Fas ligand system and cancer: immune privilege and apoptosis. Mol Biotechnol 2003; 25: 19-30
15. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997; 18: 240-244
16. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 1995; 95: 2633-2643
17. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 94: 695-698
18. Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. J Pathol 2003; 201: 268-277
19. Lee TB, Min YD, Lim SC, Kim KJ, Jeon HJ, Choi SM, Choi CH. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells. J Gastroenterol Hepatol 2002; 17: 32-38
20. Lim SC. Fas-related apoptosis in gastric adenocarcinoma. Oncol Rep 2003; 10: 57-63
21. Ungefroren H, Voss M, Henne-Bruns D, Kremer B, Kalthoff H. CD95 resistance and Fas ligand synthesis as mechanism of defense by immunocompetent cells in pancreatic tumors. Langenbecks Arch Chir Suppl Kongressbd 1998; 115(Suppl I): 63-67
22. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003; 9: 5113-5119
23. Asanuma K, Tsuji N, Endoh T, Yagihashi A, Watanabe N. Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J Immunol 2004; 172: 3922-3929
24. Houston A, Bennett MW, O'Sullivan GC, Shanahan F, O'Connell J. Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br J Cancer 2003; 89: 1345-1351
25. Yang BC, Lin HK, Hor WS, Hwang JY, Lin YP, Liu MY, Wang YJ. Mediation of enhanced transcription of the IL-10 gene in T cells, upon contact with human glioma cells, by Fas signaling through a protein kinase A-independent pathway. J Immunol 2003; 171: 3947-3954
26. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003; 63: 5573-5581
27. Whiteside TL. Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 2002; 12: 43-50
28. Didenko VV, Ngo HN, Minchew C, Baskin DS. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg 2002; 96: 580-584
29. Koyama S. Apoptotic depletion of infiltrating mucosal lymphocytes associated with Fas ligand expression by Helicobacter pylori-infected gastric mucosal epithelium: human glandular stomach as a site of immune privilege. Dig Dis Sci 2000; 45: 773-780
30. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: the Fas counterattack. Dis Esophagus 1999; 12: 83-89
31. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192
32. Muller L, Kiessling R, Rees RC, Pawelec G. Escape mechanisms in tumor immunity: an update. J Environ Pathol Toxicol Oncol 2002; 21: 277-330
33. Benchetrit F, Gazagne A, Adotevi O, Haicheur N, Godard B, Badoual C, Fridman WH, Tartour E. Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy. Bull Cancer 2003; 90: 677-685